Pear Therapeutics, Inc. reaffirmed revenue guidance for the full year 2022. For the year, reaffirmed its $22 million revenue guidance.
Pear Therapeutics, Inc.
Equities
PEAR
US7047231052
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% |
|
-.--% | -.--% |
05-23 | Pear Therapeutics, Inc. Went Out of Business | CI |
05-08 | Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- PEAR Stock
- News Pear Therapeutics, Inc.
- Pear Therapeutics Reaffirms Revenue Guidance for the Full Year 2022